Top of Form

Menggang Yu, Ph.D. Assistant Professor Indiana University School of Medicine 410 West 10th Street, Suite 3000 Indianapolis, IN 46202 email: meyu@iupui.edu Tel: (317) 278-5471, Fax: (317) 274-2678

Education

Ph.D. Biostatistics (2003), University of Michigan, Ann Arbor, MI.

M.S. Statistics (1999), Bowling Green State University, Bowling Green, OH.

B.A. Computational Mathematics (1996), Fudan University, Shanghai, China.

Research interests

Survival analysis, sequential design and models, clinical trial and Bayesian methods.

Collaborations

I oversee clinical trial design and statistical analyses for the Hoosier Oncology Group (HOG). HOG operates as a cancer research organization established to evaluate innovative and promising methods and approaches to cancer treatment through, among other things, clinical research. I also participate in many NIH funded grants, including biomarker discovery for various cancer types, pre-clinical studies, cancer screening, and cancer behavior studies.

Teaching

I enjoy interactive teaching to non-biostatistics major students and physicians. Here is a list of courses I am involved in teaching.

· Experimental Design and Research Biostatistics (G855)

· Introduction to Biostatistics (G651)

· Advanced Survival Analysis (BIOS 636)

· Longitudinal Data Analysis (Short Course Series)

· Introduction to Survival Analysis (Short Course Series)

　

Publications

　

       Here is a list of selected publications. Click here for a comprehensive list of publications.

· Statistical Methodology

1. M. Yu and B. Nan (2009). Regression Calibration in Semiparametric Accelerated Failure Time Models. Biometrics, In press.

2. B. Nan, J. D. Kalbfleish, and M. Yu (2009). Asymptotic Theory for the semiparametric accelerated failure time model with missing data. Annals of Statistics. 37, 2531-76.

3. M. Yu, J. M.G. Taylor, H. M. Sandler (2008). Individual Prediction in Prostate Cancer Studies Using a Joint Longitudinal-Survival-Cure Model. Journal of the American Statistical Association. 103, 178-187.

4. M. Yu, S. Kim, Z. Wang, S. Hall, and L. Li (2008). A Bayesian Meta-Analysis on Published Sample Mean and Variance Pharmacokinetic Data with Application to Drug-Drug Interaction Prediction. Journal of Biopharmaceutical Statistics. 18, 1063-1083.

5. L. Li, M. Yu, R. Chin, A. Lucksiri, D. Flockhart, and S. Hall (2007). Drug-Drug Interaction Prediction: A Bayesian Meta-Analysis Approach. Statistics in Medicine. 26, 3700-3721.

6. B. Nan, M. Yu and J. D. Kalbfleish (2006). Censored Linear Regression for Case-Cohort Studies. Biometrika. 93, 747-762.

7. M. Yu and B. Nan (2006). A Hybrid Newton-Type Method for Censored Survival Data Using Double Weights in Linear Models.  Lifetime data analysis. 12, 345-364.

8. M. Yu and B. Nan (2006). A Revisit of Semiparametric Regression Models with Missing Data. Statistica Sinica. 16, 1193-1212.

9. M. Yu, N. J. Law, J. M.G. Taylor, H. M. Sandler (2004). Joint Longitudinal-Survival-Cure Models and Their Application to Prostate Cancer. Statistica Sinica, 14, 835-862.

10. J.M.G. Taylor and M. Yu (2002). Bias and Efficiency Loss due to Categorizing an Explanatory Variable. Journal of Multivariate Analysis, 83, 248-263.

　

· Statistical Application

1. J.S. Carpenter, M. Yu, J. Wu, D. Von Ah, J. Milata, J.L. Otte, S. Johns, B. Schneider, A.M. Storniolo, R. Salomon, Z. Desta, J. Cao, Y. Jin, S. Phillips, T. Skaar (2009). Evaluating the Role of Serotonin in Hot Flashes after Breast Cancer Using Acute Tryptophan Depletion, Menopause: Journal of the North American Menopause Society. 16, 644-52.

2. N.M. Hahn, R.T. Zon, M. Yu, F.O. Ademuyiwa, T. Jones, W. Dugan, C. Whalen, R. Shanmugam, T. Skaar, C.J. Sweeney (2009). A Phase II Study of Pemetrexed as Second-Line Chemotherapy for the Treatment of Metastatic Castrate Resistant Prostate Cancer (CRPC). Annals of Oncology. In Press.

3. J. DeWitt, M. Yu, M.A. Al-Haddad, S. Sherman, L. McHenry, J. Leblanc (2009). Survival in patients with pancreatic cancer following the diagnosis of malignant ascites or liver metastases by EUS-FNA. Gastrointestinal Endoscopy. In Press.

4. J. Zhou, Z. Qin, S. K. Quinney, S. Kim, Z. Wang, M. Yu, A. Lucksiri, Z. Wang, S. Kim, J.Y. Chien, S. D. Hall, L. Li (2009). A New Probabilistic Rule for Drug-Dug Interaction Prediction. Journal of Pharmacokinetics and Pharmacodynamics. 36, 1-18.

5. F.C. Yang, D. A. Ingram, S. Chen, Y. Zhu, J. Yuan, X. Li, X. Yang, S. Knowles, W. Horn, Y. Li, S. Zhang, Y. Yang, S.T. Vakili, M. Yu, D. Burns, K. Robertson, G. Hutchins, L.F. Parada, D.W. Clapp (2008).  Nf1-dependent tumors require a microenvironment containing Nf1^+/- - and c-kit-dependent bone marrow. Cell. 135, 437-448.

6. X. Wu, S.A. Estwick, S. Chen, M. Yu, W. Ming, T.D. Nebesio, Y. Li, J. Yuan, K. Reuben, D. Ingram, M.C. Yoder, F.C. Yang (2006). Neurofibromin plays a critical role in modulating osteoblast differentiation of mesenchymal stem cells. Human Molecular Genetics, 15, 2837-45.

7. M. Cavalier, J.A. Shmalo, M. Yu, S.D. Billings, and R. P. Nelson (2006). Skin Cancer after Nonmyeloablative Hematopoietic Cell Transplantation. Bone Marrow Transplantation, 37, 1103-8.

8. M.D. Estes, R. Govindan, J. Vinson, T. Breen, M. Yu,  L. Einhorn, N. Hanna (2006). A phase II Trial of Gefitinib (Iressa) in Patients with Chemosensitive and Chemorefractory Relapsed Neuroendocrine Cancers.  A Hoosier Oncology Group Trial. Lung Cancer, 52, 93-97. 

9. J.M.G. Taylor, M. Yu, H. M. Sandler (2005), Individualized Predictions of Disease Progression Following Radiation Therapy for Prostate Cancer. Journal of Clinical Oncology. 23, 816-825. 

10. R.J. Chan, M. B. Leedy, V. Munugalavadla, C.S. Voorhorst, Y. Li, M. Yu, and R. Kapur (2005). Human Somatic PTPN11 Mutations Induce Hematopoietic Cell Hypersensitivity to Granulocyte-Macrophage Colony Stimulating Factor. Blood. 105: 3737-3742.